AFT Pharmaceuticals - Edison Group

Overview
Price performance
Financials
Research
Thematics

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

AFT Pharmaceuticals is a multi-product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offer it a competitive advantage in a fragmented industry.

Latest Insights

View More

Healthcare |
Flash note

04.11.24

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

Healthcare |
Flash note

30.09.24

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

Healthcare |
edison tv

26.09.24

AFT Pharmaceuticals – executive interview

Healthcare |
Flash note

09.08.24

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic

AFT-Pharmaceuticals_resized

Sector

Healthcare

Equity Analyst

Analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

David Flacks

Chairman
Dr Hartley Atkinson

CEO
Malcolm Tubby

Chief Financial Officer
Michael Weinmann

Member of the Board of Directors
Nathan D. Hukill

Member of the Board of Directors

Balance Sheet

Forecast net debt (NZ$m)

7.6

Forecast gearing ratio (%)

7

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(21.4)	(19.6)	(22.1)
Relative	(20.8)	(19.7)	(29.3)
52 week high/low	3.8/2.4

Financials

AFT Pharmaceuticals is a profitable New Zealand-based specialty pharmaceutical company that sells over 150 proprietary branded and generic products through its own salesforce in New Zealand and Australia, with offices across the globe to handle its growing export business. AFT reported strong FY24 results, with 24.8% y-o-y top-line growth, and targets an FY25 operating profit of NZ$22–25m, excluding any potential licensing income. It launched Maxigesic IV in the US in February 2024, and continues to focus on portfolio expansion and geographical diversification, including signing an exclusive licence agreement in China in September 2024. It recently announced a new R&D candidate for keloid and hypertrophic scarring, manufacturing agreements for Maxigesic Rapid and Crystaderm, partnership expansion with Hikma (to expand in the Middle East), entry into the UK and a licensing deal for Maxigesic IV in Brazil.

Y/E Mar	Revenue (NZ$m)	EBITDA (NZ$m)	PBT (NZ$m)	EPS (c)	P/E (x)	P/CF (x)
2023A	156.6	21.4	16.7	11.0	24.1	26.1
2024A	195.4	26.2	23.0	15.8	16.8	17.8
2025E	232.4	26.6	23.6	16.5	16.1	17.1
2026E	278.3	43.4	40.8	28.3	9.4	9.7

AFT-Pharmaceuticals_resized

Flash note

Healthcare

22.01.24

AFT Pharmaceuticals — Another R&D asset in the bag

AFT-Pharmaceuticals_resized

Flash note

Healthcare

22.12.23

AFT Pharmaceuticals — R&D pipeline strengthens with new candidate

AFT-Pharmaceuticals_resized

Update

Healthcare

27.11.23

AFT Pharmaceuticals — Global growth despite tough macro environment

Flash note

Healthcare

19.10.23

AFT Pharmaceuticals — FDA nod for opioid alternative, upside anticipated

Flash note

Healthcare

31.08.23

AFT Pharmaceuticals — Judgment clears AFT of lump sum payment claim

AFT-Pharmaceuticals_resized

Update

Healthcare

24.05.23

AFT Pharmaceuticals — Near-term goals in sight with FY23 momentum

Plate of pills. Background or texture

Flash note

Healthcare

02.05.23

AFT Pharmaceuticals — Maxigesic IV closer to FDA approval

Flash note

Healthcare

28.03.23

AFT Pharmaceuticals — Maxigesic international momentum continues

AFT-Pharmaceuticals_resized

Flash note

Healthcare

02.03.23

AFT Pharmaceuticals — Big win with Maxigesic Rapid’s FDA nod

Flash note

Healthcare

02.02.23

AFT Pharmaceuticals — Portfolio expansion with new in-licensing deal

AFT-Pharmaceuticals_resized

Flash note

Healthcare

25.01.23

AFT Pharmaceuticals — Maxigesic IV expands into East European markets

Flash note

Healthcare

10.01.23

AFT Pharmaceuticals — Progressive outlook for CY23

Update

Healthcare

24.11.22

AFT Pharmaceuticals — H123 focused on portfolio expansion

Flash note

Healthcare

07.09.22

AFT Pharmaceuticals — Further studies for Maxigesic IV’s US nod

Plate of pills. Background or texture

Flash note

Healthcare

02.09.22

AFT Pharmaceuticals — Collaboration for developing birthmark medicine

Flash note

Healthcare

28.07.22

AFT Pharmaceuticals — Pascomer falls short of FDA mandated threshold

Flash note

Healthcare

08.07.22

AFT Pharmaceuticals — Expanding reach into China

Flash note

Healthcare

06.07.22

AFT Pharmaceuticals — Maxigesic IV hits a roadblock in the US

Update

Healthcare

16.06.22

AFT Pharmaceuticals — Re-acceleration leveraging its platform

Plate of pills. Background or texture

Flash note

Healthcare

25.05.22

AFT Pharmaceuticals — Recovery driven by strong H222

Update

Healthcare

22.11.21

AFT Pharmaceuticals — 14% revenue growth despite COVID-19 headwinds

Update

Healthcare

26.05.21

AFT Pharmaceuticals — Growth in the face of a challenging environment

Update

Healthcare

24.11.20

AFT Pharmaceuticals — Growth despite COVID-19 challenges

Update

Healthcare

21.05.20

AFT Pharmaceuticals — Solid FY20 results

Plate of pills. Background or texture

Outlook

Healthcare

25.11.19

AFT Pharmaceuticals — A strong start to FY20

Update

Healthcare

10.07.19

AFT Pharmaceuticals — A licensing deal for Pascomer

Update

Healthcare

28.05.19

AFT Pharmaceuticals — Operating profitability achieved

Update

Healthcare

30.11.18

AFT Pharmaceuticals — Margins improving

Update

Healthcare

30.05.18

AFT Pharmaceuticals — Strong FY18 results

Plate of pills. Background or texture

Update

Healthcare

28.03.18

AFT Pharmaceuticals — Improving profitability

Outlook

Healthcare

12.12.17

AFT Pharmaceuticals — Australia and Maxigesic driving growth

Update

Healthcare

31.05.17

AFT Pharmaceuticals — On the cusp

research

Healthcare

20.01.17

AFT Pharmaceuticals — Updates on several products

Update

Healthcare

05.12.16

AFT Pharmaceuticals — Update 5 December 2016

Plate of pills. Background or texture

Initiation

Healthcare

31.05.16

AFT Pharmaceuticals — Update 31 May 2016

QuickView

Healthcare

22.12.15

AFT Pharmaceuticals — Update 21 December 2015